2/25
07:18 am
ird
Opus Genetics Announces FDA Acceptance of Supplemental New Drug Application for Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia [Yahoo! Finance]
Medium
Report
Opus Genetics Announces FDA Acceptance of Supplemental New Drug Application for Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia [Yahoo! Finance]
2/25
06:59 am
ird
Opus Genetics Announces FDA Acceptance of Supplemental New Drug Application for Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia
Medium
Report
Opus Genetics Announces FDA Acceptance of Supplemental New Drug Application for Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia
2/22
09:40 pm
ird
Opus Genetics: Asymmetric Upside With LCA5 And BEST1 [Seeking Alpha]
Neutral
Report
Opus Genetics: Asymmetric Upside With LCA5 And BEST1 [Seeking Alpha]
2/13
02:48 pm
ird
Update: Opus Genetics Shares Rise After Announcement of $25 Million Private Placement [Yahoo! Finance]
Low
Report
Update: Opus Genetics Shares Rise After Announcement of $25 Million Private Placement [Yahoo! Finance]
2/13
07:30 am
ird
Opus Genetics Announces $25 Million Private Placement
Medium
Report
Opus Genetics Announces $25 Million Private Placement
2/13
06:29 am
ird
Opus Genetics (NASDAQ:IRD) was upgraded by analysts at Lifesci Capital to a "strong-buy" rating.
Medium
Report
Opus Genetics (NASDAQ:IRD) was upgraded by analysts at Lifesci Capital to a "strong-buy" rating.
2/2
08:00 am
ird
Opus Genetics to Participate in Upcoming Medical and Industry Conferences in February 2026
Low
Report
Opus Genetics to Participate in Upcoming Medical and Industry Conferences in February 2026
1/28
08:04 am
ird
Opus Genetics (NASDAQ:IRD) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $7.00 price target on the stock.
Medium
Report
Opus Genetics (NASDAQ:IRD) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $7.00 price target on the stock.
1/27
07:00 am
ird
Opus Genetics Launches Gene Therapy Clinical Trial for MERTK-related Retinitis Pigmentosa
Low
Report
Opus Genetics Launches Gene Therapy Clinical Trial for MERTK-related Retinitis Pigmentosa
1/21
06:19 am
ird
Opus Genetics (NASDAQ:IRD) was upgraded by analysts at BTIG Research to a "strong-buy" rating.
Medium
Report
Opus Genetics (NASDAQ:IRD) was upgraded by analysts at BTIG Research to a "strong-buy" rating.
1/20
07:01 am
ird
Opus Genetics (NASDAQ:IRD) is now covered by analysts at BTIG Research. They set a "buy" rating on the stock.
Medium
Report
Opus Genetics (NASDAQ:IRD) is now covered by analysts at BTIG Research. They set a "buy" rating on the stock.
1/8
07:00 am
ird
Opus Genetics Highlights 2025 Progress and Upcoming 2026 Catalysts
Medium
Report
Opus Genetics Highlights 2025 Progress and Upcoming 2026 Catalysts
1/3
01:08 am
ird
Low
Report
12/20
03:10 pm
ird
The 2 Riskiest Stocks Investors Are Betting On With Over 300% Upside [Yahoo! Finance]
Low
Report
The 2 Riskiest Stocks Investors Are Betting On With Over 300% Upside [Yahoo! Finance]
12/16
04:01 pm
ird
Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
12/11
07:00 am
ird
Opus Genetics to Present at the J.P. Morgan 2026 Healthcare Conference
Low
Report
Opus Genetics to Present at the J.P. Morgan 2026 Healthcare Conference
12/9
09:03 pm
ird
Opus Genetics (NASDAQ:IRD) is now covered by analysts at B. Riley. They set a "buy" rating on the stock.
Medium
Report
Opus Genetics (NASDAQ:IRD) is now covered by analysts at B. Riley. They set a "buy" rating on the stock.
12/9
07:00 am
ird
Opus Genetics Announces Positive Recommendation from Independent Data Monitoring Committee for Phase 1/2 Trial in Best Disease
Medium
Report
Opus Genetics Announces Positive Recommendation from Independent Data Monitoring Committee for Phase 1/2 Trial in Best Disease
12/2
04:01 pm
ird
Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
12/2
06:16 am
ird
Opus Genetics (NASDAQ:IRD) was upgraded by analysts at Brookline Capital Management to a "strong-buy" rating.
Low
Report
Opus Genetics (NASDAQ:IRD) was upgraded by analysts at Brookline Capital Management to a "strong-buy" rating.
11/29
01:34 am
ird
Piper Sandler Initiates Coverage on Opus Genetics, Inc. (IRD) With “Overweight” Rating and $7 PT [Yahoo! Finance]
Medium
Report
Piper Sandler Initiates Coverage on Opus Genetics, Inc. (IRD) With “Overweight” Rating and $7 PT [Yahoo! Finance]